Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

82.40 +0.06 (+0.07%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,977,723
Open 82.18
Bid (Size) 81.08 (1)
Ask (Size) 83.75 (7)
Prev. Close 82.34
Today's Range 81.50 - 82.55
52wk Range 61.24 - 86.57
Shares Outstanding N/A
Dividend Yield 1.25%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
AI Revolutionizes Pharma: Smarter Excipients for Safer, More Potent Drugs
San Francisco, CA – October 31, 2025 – Artificial intelligence (AI) is ushering in a transformative era for the pharmaceutical industry, particularly in the often-overlooked yet critical domain of... 
Via TokenRing AI
Topics Artificial Intelligence Supply Chain
AI: The Pharmaceutical Sector’s New Catalyst for a Healthier Future
The pharmaceutical industry is in the midst of a profound and rapid transformation, driven by the pervasive integration of Artificial Intelligence (AI). What was once a futuristic concept is, by late... 
Via TokenRing AI
Topics Animal Testing Artificial Intelligence Economy

Performance

YTD
+25.1%
+25.1%
1 Month
-2.3%
-2.3%
3 Month
+11.4%
+11.4%
6 Month
+13.7%
+13.7%
1 Year
+15.8%
+15.8%

More News

Read More
AstraZeneca’s Enhertu Achieves Record Response Rate In Phase 3 Trial For Early Breast Cancer
Via Stocktwits
Alnylam Stock Has Already Doubled In 2025. Why It Could Rocket Again On Earnings.
Via Investor's Business Daily
Sanofi Soars as Dupixent Sales Near €5 Billion Amidst Intensifying Trump Drug Pricing Negotiations
Via MarketMinute
Topics Government World Trade
3 Pharmaceutical Growth Stocks to Buy and Hold for 10 Years
Via MarketBeat
Eccogene Eyes Hong Kong IPO With Experimental Weight-Loss Drug, AstraZeneca Partnership
Via Benzinga
Topics Initial Public Offering
Nurix Therapeutics (NASDAQ: NRIX) Stock Soars as Pivotal Phase 2 Study for Bexobrutideg Ignites Investor Confidence
Via MarketMinute
Danaher Corporation Poised for Growth as Q3 2025 Earnings Spark Optimism
Via MarketMinute
Peering Into AstraZeneca PLC's Recent Short Interest
Via Benzinga
DATROWAY® (datopotamab deruxtecan-dlnk) demonstrated unprecedented median overall survival improvement of five months vs. chemo as 1st-line treatment for patients with metastatic triple-negative breast cancer for whom immunotherapy was not an option
From AstraZeneca
Via Business Wire
ENHERTU® (fam-trastuzumab deruxtecan-nxki) reduced the risk of disease recurrence or death by 53% vs. T-DM1 in patients with high-risk HER2-positive early breast cancer following neoadjuvant therapy in DESTINY-Breast05 Phase III trial
From AstraZeneca
Via Business Wire
AstraZeneca, In A Buy Zone, Makes A Big Breast Cancer Splash
Via Investor's Business Daily
ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery resulted in a pathologic complete response in 67% of patients with high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11 Phase III trial
From AstraZeneca
Via Business Wire
TEZSPIRE approved in the US for chronic rhinosinusitis with nasal polyps
From AstraZeneca
Via Business Wire
Invo Fertility Stock Is Plunging After White House Announcement
Via Benzinga
IMFINZI® (durvalumab) regimen reduced the risk of disease recurrence or death by 32% in high-risk non-muscle-invasive bladder cancer in the POTOMAC Phase III trial
From AstraZeneca
Via Business Wire
IMFINZI® (durvalumab)-based regimen reduced the risk of death by 22% in early gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial
From AstraZeneca
Via Business Wire
UK Finance Minister Seeks More Pharma Investment In Exchange For Higher Drug Prices: Report
Via Benzinga
Merck's Keytruda Plus Chemo Regimen Shows Overall Survival Benefit In Recurrent Ovarian Cancer Patients
Via Benzinga
2 Pharmaceutical Growth Stocks to Buy Now and Hold for Decades
Via The Motley Fool
Eli Lilly's Oral Weight Loss Drug Shows Superiority Over Two Approved Drugs
Via Benzinga
AstraZeneca Unveils Expanded Facility In Texas Aimed At Doubling Production Of Hyperkalemia Drug
Via Stocktwits
AstraZeneca unveils expanded manufacturing facility in Texas
From AstraZeneca
Via Business Wire
AstraZeneca PLC (NASDAQ:AZN): A Caviar Cruise Quality Investment
Via Chartmill

Frequently Asked Questions

Is AstraZeneca PLC - American Depositary Shares publicly traded?
Yes, AstraZeneca PLC - American Depositary Shares is publicly traded.
What exchange does AstraZeneca PLC - American Depositary Shares trade on?
AstraZeneca PLC - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for AstraZeneca PLC - American Depositary Shares?
The ticker symbol for AstraZeneca PLC - American Depositary Shares is AZN on the Nasdaq Stock Market
What is the current price of AstraZeneca PLC - American Depositary Shares?
The current price of AstraZeneca PLC - American Depositary Shares is 82.40
When was AstraZeneca PLC - American Depositary Shares last traded?
The last trade of AstraZeneca PLC - American Depositary Shares was at 10/31/25 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.